Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
about
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesPersistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritisEfficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phasPersistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line.Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.Advances in the management of psoriatic arthritis.Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides.Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.Certolizumab pegol for the treatment of psoriatic arthritis.Pharmacological therapy of spondyloarthritis.Psoriatic arthritis: latest treatments and their place in therapy.Novel approaches to biological therapy for psoriatic arthritis.Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature.Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.Switching of biologics in psoriasis: Reasons and results.Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option?Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectivesPatterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims databaseSecukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
P2860
Q26764867-DABD6B62-84FC-40F7-995C-4048634154C9Q33563272-30699516-2636-4F34-8B19-5158B94BEDFCQ33659249-AC771B5A-5E50-40C7-9C72-9E217B762812Q37596119-2052B644-60C8-4AC5-889C-FFC2F20A8760Q38189853-A47D7053-A6DA-481E-BA76-4EE37DA8D73EQ38227264-EB9C61FD-AC4A-4A40-B9BB-BFBDD6344CD3Q38238931-F4B8BAFC-7196-4FF9-A892-50F2356A9061Q38264660-719EB398-4A4B-43CD-8A10-CBB91CE36A50Q38344194-5AEC0526-1AC4-4F85-B28C-8BFAA9F9B7E1Q38527552-3958C586-E59F-42C1-B8CD-621E9BB9BD4CQ38542095-CBFBB763-8939-4713-91B5-F598BF57AF3EQ38634276-9CAB0D39-92DD-469E-ACD9-2841D4915EFCQ38978414-043FB3C6-D196-4A7A-9144-5EBB74EC29B2Q41615511-C9A66CB5-F166-4542-A3F0-AD2448D5EF01Q46129663-CF46FB29-A943-4612-A4C2-7BC927952185Q47114261-E863AC87-1325-446C-AEAC-632BBEDE70CCQ47550260-9FFF1B93-F23C-42EA-A904-862920D60E0EQ47595036-93841C0F-82F4-4A0F-9D7B-0048C85843F7Q47870337-D141C43B-6A16-4EA8-8C40-77E6D4BE6E21Q48166630-02B168CE-EA0D-4901-9D8C-4971DDB3B048Q50220930-FFEB3A1D-D37B-4704-A9DE-85B9A61DBAFBQ52653700-43A65422-D6CB-4049-A006-66BF349691D4Q53157376-1BC16814-FC14-4062-9AE1-DA3C7D6DD8B1Q53841352-F580719C-67AB-425B-96C2-F39499D3C937Q55117680-BBEE0C24-3351-44E3-A9DB-FAB7D7C2D525Q56891106-26FB310A-3553-4C40-920C-03DD1CBB5C9BQ57074034-93AD5CEF-5B62-4AF1-A89F-F1320FBBE63DQ57169747-E0CCC221-B322-4D08-B1A7-D119C07CE604
P2860
Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
@ast
Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
@en
type
label
Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
@ast
Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
@en
prefLabel
Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
@ast
Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
@en
P2093
P2860
P1476
Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
@en
P2093
Ase Stavland Lexberg
Elisabeth Lie
Erik Rødevand
Karen Minde Fagerli
Knut Mikkelsen
Marte Schrumpf Heiberg
Synøve Kalstad
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-203018
P407
P577
2013-04-05T00:00:00Z